PepVax, Inc. is an early stage life sciences technology company based in Silver Spring, MD. They have developed a novel DNA-based drug delivery and development platform for proteins, T-cells, and antibodies to be used in the treatment of cancers, infectious diseases, and genetic disorders.
The company has recently achieved significant milestones, including the completion of an efficacy study for their lead candidate, PVX-009, and winning the Best in Show at the Philadelphia 1st Pitch Life Science Competition. With a focus on revolutionizing immunotherapy, PepVax aims to make a real difference in patients' lives by partnering with larger pharmaceutical companies and continuing their growth in the field of biotechnology.
Generated from the website